Sheldon Sloan
Known title: Chief Medical OfficerCIK: 0002038798
Associated companies
Transaction History
| SYRE | ▲ Buy | Option Exercise | 8,334 | $229K | 7/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 6,500 | $569K | 7/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 1,834 | $162K | 7/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 8,333 | $229K | 6/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 8,333 | $625K | 6/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 10,358 | $764K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 12,777 | $932K | 5/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 78,333 | $2.2M | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 21,306 | $1.5M | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 19,656 | $1.4M | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 8,777 | $628K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 5,059 | $377K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 400 | $30K | 5/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 7,958 | $172K | 4/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 7,958 | $398K | 4/1/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Spyre Therapeutics Launches $350M Public Offering, Stock Drops
Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.
Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.